Shares in Samsung's drug-making unit soared almost six percent on their market debut Thursday, after one of South Korea's biggest ever initial public offerings that raised nearly $2 billion.
Samsung Biologics, a contract manufacturer of biotech drugs for global pharmaceutical firms, surged 5.88 percent from its IPO price to close at 144,000 won ($125) in Seoul, putting its total value at about 9.5 trillion won. The rally came as investors snapped up pharmaceutical shares after Donald Trump victory in the US presidential election, during which rival Hillary Clinton had said she would move to lower drugs prices.
The pharma sector rallied eight percent in Seoul. Samsung Biologics was set up by the South Korean conglomerate in 2011 as part of a multi-billion-dollar drive to find new growth avenues including healthcare and green energy over the next decade. The highly anticipated IPO is the second largest in South Korea's history, raising 2.25 trillion won ($1.96 billion), which the unit says will be used to expand production capacity and invest in research and development. The firm makes biopharmaceutical drugs for major firms including Bristol-Myers Squibb and Roche at plants near Seoul.
Bio-drugs, unlike chemically synthesised drugs, are made of organic, live substances such as plant or animal cells and are more complex to research and manufacture. Construction unit Samsung C&T and the flagship Samsung Electronics together hold a 75 percent stake in Samsung Biologics after the share sale. The firm has been in the red for years with a net loss of 75.7 billion won in 2015 as it invested heavily in its two existing plants and a new facility slated to open in two years.
Comments
Comments are closed for this article.